| Mrs Nicole Rae Summers, DO | |
|
2400 N Washington Blvd, North Ogden, UT 84414-7233 | |
| (801) 442-3059 | |
| Not Available |
| Full Name | Mrs Nicole Rae Summers |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 2400 N Washington Blvd, North Ogden, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467753798 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 8527A (Wyoming) | Secondary |
| 208D00000X | General Practice | 8527A (Wyoming) | Secondary |
| 207Q00000X | Family Medicine | 10232585-1204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
The New research published in The Journal of Physiology has shown that ketone supplements may be a novel therapeutic strategy for protecting and improving brain health in people with obesity.
Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Asking parents just two simple screening questions could help health care providers and social workers to easily and quickly identify families whose young children are suffering from hunger, enabling early interventions that could prevent serious health consequences, according to a new study led by University of Maryland School of Medicine researchers. The study, published July 1 in the journal Pediatrics, analyzed data gathered from more than 30,000 families nationwide, about a quarter of whom suffered from hunger.
Adenoviruses cause numerous diseases, such as eye or respiratory infections, and they are widely used in gene therapy. Researchers from the University of Zurich have now discovered how these viruses penetrate the cells, a key step for infection and gene delivery. The cell unwillingly supports virus entry and infection by providing lipids that are normally used to repair damaged membranes.
› Verified 3 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
The New research published in The Journal of Physiology has shown that ketone supplements may be a novel therapeutic strategy for protecting and improving brain health in people with obesity.
Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Asking parents just two simple screening questions could help health care providers and social workers to easily and quickly identify families whose young children are suffering from hunger, enabling early interventions that could prevent serious health consequences, according to a new study led by University of Maryland School of Medicine researchers. The study, published July 1 in the journal Pediatrics, analyzed data gathered from more than 30,000 families nationwide, about a quarter of whom suffered from hunger.
Adenoviruses cause numerous diseases, such as eye or respiratory infections, and they are widely used in gene therapy. Researchers from the University of Zurich have now discovered how these viruses penetrate the cells, a key step for infection and gene delivery. The cell unwillingly supports virus entry and infection by providing lipids that are normally used to repair damaged membranes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Nicole Rae Summers, DO Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 442-3059 | Mrs Nicole Rae Summers, DO 2400 N Washington Blvd, North Ogden, UT 84414-7233 Ph: (801) 442-3059 |
News Archive
The New research published in The Journal of Physiology has shown that ketone supplements may be a novel therapeutic strategy for protecting and improving brain health in people with obesity.
Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Asking parents just two simple screening questions could help health care providers and social workers to easily and quickly identify families whose young children are suffering from hunger, enabling early interventions that could prevent serious health consequences, according to a new study led by University of Maryland School of Medicine researchers. The study, published July 1 in the journal Pediatrics, analyzed data gathered from more than 30,000 families nationwide, about a quarter of whom suffered from hunger.
Adenoviruses cause numerous diseases, such as eye or respiratory infections, and they are widely used in gene therapy. Researchers from the University of Zurich have now discovered how these viruses penetrate the cells, a key step for infection and gene delivery. The cell unwillingly supports virus entry and infection by providing lipids that are normally used to repair damaged membranes.
› Verified 3 days ago
Dr. Matthew Gunn Weeks, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Washington Blvd, North Ogden, UT 84414 Phone: 801-786-7500 | |
Dr. Lee Carl Schussman, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2400 N Washington Blvd, North Ogden, UT 84414 Phone: 801-786-7500 | |
Jean Mcguire, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Washington Blvd, North Ogden, UT 84414 Phone: 801-786-7500 | |
Dr. Randall L Steinfeldt, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Washington Blvd, North Ogden, UT 84414 Phone: 801-786-7500 | |
Benjamin Barraclough, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Washington Blvd, North Ogden, UT 84414 Phone: 801-786-7500 | |
Dr. Chad Ryan Jensen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Washington Blvd, North Ogden, UT 84414 Phone: 801-786-7500 Fax: 801-737-9531 |